Carl June (Brian Ach/Getty Images for TIME 100 Health Summit)
May 6, 2024 03:54 PM EDT
R&D
Cell/Gene Tx

UPenn and Stan­ford analy­sis finds no sec­ondary can­cer cas­es di­rect­ly due to CAR-T

Lei Lei Wu

News Reporter

The Uni­ver­si­ty of Penn­syl­va­nia’s pi­o­neer­ing cell ther­a­py physi­cian Carl June shared new da­ta Mon­day that showed the risk of sec­ondary can­cers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times